BeiGene welcomes the return of the immunotherapy’s rights as an opportunity to make it the backbone of its solid tumors strategy. But Novartis cedes an opportunity to gain a competitor to established cancer immunotherapies from Merck and Bristol Myers Squibb.

Cernostics is part of the wave of oncology that looks at cancer at the tissue and cellular level instead of focusing on the location of the tumor — lung, stomach, pancreas.